BioWorld

May 20, 2004

View Archived Issues

Phase III Antegren Data Show Benefit For Crohn's Continues

Offering new data for Antegren against Crohn's disease, Biogen Idec Inc. said it will file for approval in the European Union but is conducting another study in the U.S. before seeking approval here. (BioWorld Today) Read More

Senate Passes BioShield In 99-0 Vote; $5.6B Slated For Industry

Read More

Two Companies Spun Out Of Seattle Incubator Organization

Read More

J&J, Centocor Acquiring Egea For Protein Design Technology

Read More

Other News To Note

Read More

Appointments And Advancements

Read More